Replies to post #255505 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

My WAG pm 3-71. It promotes cellular homeostasis in a slightly different manner and in the future 2-73 or 3-71 may be chosen because one compensates for specific epigenetic mutations more efficiently than the other.

[pcguy]

A3-71 has a different molecular structure and targets different muscarinic receptors. Muscarinic receptors play various roles throughout the body, which is why I believe A2-73 has benefit beyond memory loss. A2-73 interacts with all the muscarinic receptor types, which can help things like your heart, stomach, and muscle movement. A3-71 is designed to specifically target M1 receptors, or those that help with brain function. The molecule is also smaller and has a higher affinity for sigma 1 and M1 receptors, possibly making it more effective. It may not have some of the beneficial side effects that A2-73 has because of this. It has been a long time since I have researched these. A3-71 is what brought me here to invest.

[tredenwater2]

“ It allows AVXL to partner on 2-73 but maintain all ownership of 3-71...a potentially more effective sigma 1 agonist that is cheaper to manufacture ”

I agree and dont forget about the Priority Revue Voucher if Rett Syndrome gets approved out of our FDA Fastrack program!

“Full speed ahead Scottie!” “Eye eye captain!”